ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore Walking after Paralysis
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported that a new study by scientists at .NeuroRestore, ONWARD’s research partner, has identified the specific neurons that are activated and remodeled by spinal cord stimulation, enabling individuals with spinal cord injury to stand, walk and rebuild their muscles. This discovery marks a fundamental, scientific breakthrough. The study was published yesterday in Nature.
In the multi-year STIMO study, coordinated by .NeuroRestore’s co-directors – Grégoire Courtine, a neuroscience professor at EPFL and Chief Scientific Officer of ONWARD, and Jocelyne Bloch, a neurosurgeon at Lausanne University Hospital (CHUV) – participants with paralysis due to spinal cord injury underwent targeted epidural electrical stimulation of the area of the spinal cord that controls leg movement. Remarkably, all participants regained motor function and the ability to walk. Three participants in the study pioneered use of an innovative lead developed by ONWARD to specifically target the areas of the spinal cord involved in leg and lower trunk movement with the intent to facilitate faster and more effective recovery of motor function.
The scientists believe it is crucial to understand exactly how neuronal reorganization occurs to develop more effective treatments and improve the lives of as many people as possible. The press release by EPFL can be found here.
“The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis. As a result of this study and its accompanying scientific breakthrough, ONWARD and its research partners have learned precisely where to place the epidural lead and how to program stimulation to facilitate walking,” said Dave Marver, CEO of ONWARD. “This important work is enabling us to develop a therapy for people with spinal cord injury that aims to be precise, repeatable, and scalable.”
About ONWARD Medical
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.
ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IMand ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of ARC-EX Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.
ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For Company Enquiries:
For Media Enquiries:
MC Services AG
U.S.: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka P: +49 89 210 228 0
For Investor Enquiries:
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Limited Libations, Innovative Blending, Escapism Elixirs and More are Shaping the Way That Consumers Drink in 2024, Based on the Bacardi Cocktail Trends Report4.12.2023 16:40:00 CET | Press release
Bacardi Limited, the world’s largest privately held international spirits company, releases its fifth annual Bacardi Cocktail Trends Report, anticipating the key trends that will redefine cocktail culture and the spirits business in 2024. The report, created in collaboration with strategic foresight consultancy, The Future Laboratory (TFL), draws on insights from Bacardi-led and external research, interviews with bartenders and insights from The Future Laboratory to share the themes that are transforming flavor preferences, drink formats, and cocktail experiences in the coming year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231202332985/en/ Find out what's in store for 2024 with the Bacardi Cocktail Trends Report. (Graphic: Business Wire) “As 2024 arrives, people are looking to settle into the unsettled – welcoming tastes of optimism into our reality. In this landscape, people are reshaping cocktail culture, infusing it
Visa and Oxfam America to Explore Expanding Anticipatory Action Program to Bring Pre-Disaster Financial Support to the Philippines, Kenya, Colombia, and Puerto Rico4.12.2023 15:00:00 CET | Press release
During the 28th United Nations Climate Change Conference (COP28), Visa (NYSE: V), a global leader in digital payments, and Oxfam America, a part of the global Oxfam organization fighting inequality to end poverty and injustice, announced intent to collaborate to scale Oxfam’s Building Resilient, Adaptive and Disaster-Ready Communities (B-READY) project to deliver real-time streamlined money movement and relief payments to individuals and businesses in the Philippines, Kenya, Colombia, and Puerto Rico. B-READY unites parametric forecasting with community inputs to provide humanitarian assistance to individuals, communities, and businesses before a disaster strikes. Visa and Oxfam America intend to scale B-READY to create a mobile-based payment solution infrastructure to digitize humanitarian payments to help families, individuals, and small businesses protect themselves and their assets before a disaster. Combining data-driven insights from Visa with Oxfam’s record of disaster relief an
QPS Holdings, LLC Expands Operations in Springfield, Missouri4.12.2023 14:30:00 CET | Press release
QPS Holdings, LLC, a global contract research organization has expanded operations in Springfield, Missouri. The new facilities include a clinical (safety) laboratory, an updated self-contained pharmacy, and a new dedicated space to build and ship clinical trial kits. The 2,750-square-foot facility is fully operational as of the fall of 2023 and will give QPS significant flexibility in clinical research study operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204471818/en/ QPS Missouri is a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials in Springfield, Missouri, and has recently added a new safety laboratory, updated pharmacy, and clinical trial kit production facility. (Photo: Business Wire) The state-of-the art laboratory is equipped with the most up-to-date technologies for Chemistry, Urinalysis, Serology, Coagulation, and Hematology test
Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib4.12.2023 14:00:00 CET | Press release
Merck, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a benign tumor of the joints that can cause swelling, pain, stiffness, and limited mobility of the affected joints. Treatment options for this disease, which can seriously affect patients’ quality of life, are very limited. The agreement grants Merck a license to commercialize pimicotinib in mainland China, Hong Kong, Macau and Taiwan, with an option for rest of world. “We have the opportunity through our partnership with Abbisko to deliver a first-in-class treatment for a critically underserved patient population in China and potentially beyond,” said Andrew Paterson, Chief Marketing Officer for the Healthcare business sector of Merck. “Pimicotinib provides an opportunity to address a significant unmet
‘AlignMiracle’ Makes Waves in the World of Direct Clear Aligner, Featured in the Prestigious International Clinical Journal, JCO4.12.2023 14:00:00 CET | Press release
ODS Co., Ltd., a leading provider of Direct Clear Aligner (also known as “Direct Print Aligner”), today announced the publication of treatment cases using direct clear aligners in the October 2023 issue of the Journal of Clinical Orthodontics (JCO), one of the most respected publications in the field of orthodontics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204386200/en/ ‘Orthodontic Treatments Using Directly 3D-Printed Clear Aligners’ published in the Journal of Clinical Orthodontics on October 2023 (Graphic: Business Wire) The Direct Clear Aligner is an orthodontic solution that designs the aligners directly on each step of setup model on the computer and prints them directly with clear resin on the 3D printer, eliminating the need for an intermediate printed teeth model involving thermoforming the sheets and trimming. Founded in 1967, JCO is an esteemed international academic journal with a rich history of over f